

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

- 1-12. (Canceled)
13. (Previously Presented) A method of inhibiting lymphocyte activation, comprising administering to a patient in need thereof an antibody that binds to a protein having an amino acid sequence encoded by the nucleotide sequence set forth in SEQ ID NO: 1.
14. (Withdrawn) A method according to claim 13, wherein the lymphocytes are T cells.
15. (Previously Presented) A method according to claim 13, wherein the lymphocytes are B cells.
16. (Previously Presented) A method according to claim 13, wherein the antibody is a monoclonal antibody.
17. (Previously Presented) A method according to claim 16, wherein the antibody comprises a constant region of human antibody.
18. (Previously Presented) A method according to claim 16, wherein the antibody is a chimeric antibody or humanized antibody.
19. (Previously Presented) A method according to claim 16, wherein the antibody is an anti-HM1.24 antibody.
20. (Previously Presented) A method according to claim 18, wherein the antibody is a chimeric anti-HM1.24 antibody.
21. (Previously Presented) A method according to claim 18, wherein the antibody is a humanized anti-HM1.24 antibody.

22. (Previously Presented) A method according to claim 1, wherein the antibody binds to an epitope recognized by an anti-HM1.24 antibody.

23. (Previously Presented) A method of treating a disease associated with lymphocyte activation, comprising administering to a patient in need thereof an antibody that binds to a protein having an amino acid sequence encoded by the nucleotide sequence set forth in SEQ ID NO: 1.

24. (Previously Presented) A method according to claim 23, wherein said disease is selected from the group consisting of autoimmune disease, rejection in organ transplantation, and allergy.